Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others

June 03 23:31 2021
Progressive Supranuclear Palsy Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | DTx Pharma, APRINOIA Therapeutics, Arvinas, Tau-Biologics, AlzProtect and Others

Progressive Supranuclear Palsy Pipeline

Progressive supranuclear palsy is a rare degenerative neurological disorder that affects movement, control of walking and balance, speech, swallowing, vision, mood and behavior, and thinking. The condition is caused by the gradual damage of brain cells. The neuropathological hallmark of PSP is a biochemical alteration in the tau protein, which results in a neurodegeneration and gliosis in the basal ganglia, brainstem, prefrontal cortex and cerebellum.

DelveInsight’s, “Progressive Supranuclear Palsy Pipeline Insight, 2021” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Progressive Supranuclear Palsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Progressive supranuclear palsy Companies are:

  • Retrotope
  • Woolsey Pharmaceuticals
  • UCB
  • Novartis Pharmaceuticals
  • EmeraMed
  • Aquinnah Pharmaceuticals
  • DTx Pharma
  • APRINOIA Therapeutics
  • Arvinas
  • Tau-Biologics
  • AlzProtect
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight

 

DelveInsight’s Progressive supranuclear palsy report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

 

Some of Progressive supranuclear palsy Therapies are:

  • RT001
  • Fasudil
  • Bepranemab (UCB 0107)
  • NIO752
  • NBMI
  • TDP-43 stress granules
  • MSUT2 programme
  • Anti tau monoclonal antibody
  • Tau-targeted PROTAC® protein degraders
  • TBL-100
  • Ezeprogind
  • And Many Others

 

Request for free sample report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight

 

Current Progressive supranuclear palsy Treatment Scenario and Progressive supranuclear palsy Emerging Therapies:

  • How many companies are developing Progressive Supranuclear Palsy drugs?
  • How many Progressive Supranuclear Palsy drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Progressive Supranuclear Palsy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Progressive Supranuclear Palsy therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Progressive Supranuclear Palsy and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free sample report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight

 

Table of Contents:

Introduction
Executive Summary
Progressive Supranuclear Palsy: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Progressive Supranuclear Palsy – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Progressive Supranuclear Palsy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Progressive Supranuclear Palsy Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Drug name: Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
RT001: Retrotope
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Bepranemab (UCB 0107): UCB
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
• Comparative Analysis
MSUT2 programme: DTx Pharma
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Progressive Supranuclear Palsy Key Companies
Progressive Supranuclear Palsy Key Products
Progressive Supranuclear Palsy- Unmet Needs
Progressive Supranuclear Palsy- Market Drivers and Barriers
Progressive Supranuclear Palsy- Future Perspectives and Conclusion
Progressive Supranuclear Palsy Analyst Views
Progressive Supranuclear Palsy Key Companies
Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-pipeline-insight


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/goaheadlines.org/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7